MRNA — Moderna, Inc.
$200.10-1.25%
Last close: · regular session
After-hours $201.34 +0.62% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MRNA in the TickerWise workspace.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 5,800
- Website: https://www.modernatx.com
Latest SEC filings for MRNA
Latest MRNA news
- Breakfast News: A Conversation With Moderna’s CEO Read article
- Analysts weigh in on Moderna's big drop following cancer vaccine results Read article
- Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? Read article
- Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports Read article
- Moderna finishes lower by 17% amid leaked cancer vaccine data Read article
- Moderna shares plunge on leaked cancer vaccine data Read article
- Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice Read article
- Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.